Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalbavancin - Durata Therapeutics

Drug Profile

Dalbavancin - Durata Therapeutics

Alternative Names: A-A-1; BI-397; Dalbavancin hydrochloride; Dalvance; MDL-63,397; V-Glycopeptide; VER 001; VGE; Xydalba; Zevan; Zeven

Latest Information Update: 22 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cipher Pharmaceuticals; Durata Therapeutics; Pfizer
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteomyelitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacterial endocarditis; Osteomyelitis
  • No development reported Bacterial infections; Catheter infections; Diabetic foot ulcer; Gonorrhoea; Pneumonia

Most Recent Events

  • 31 Dec 2023 Durata Therapeutics completes a phase III trial in Skin and soft tissue infections (In infants, In adolescents, In children) in US, Bulgaria, Chile, Guatemala, Panama, Ukraine, Mexico, Colombia, Georgia, Greece, Latvia, Lithuania and Spain.(IV) (NCT02814916)
  • 19 Jan 2022 Launched for Skin and soft tissue infections in Canada (IV)
  • 23 Jul 2021 Launched for Skin and soft tissue infections (In adolescents, In children, In infants, In neonates) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top